权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vital microscopic studies for mechanisms of antitumor lymphocyte adhesion to tumor microvessels

抗肿瘤淋巴细胞粘附肿瘤微血管机制的重要显微镜研究

基本信息

批准号：
13671403
负责人：
SOHARA Yasunori
金额：
$ 2.24万
依托单位：
Jichi Medical School
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2001
资助国家：
日本
起止时间：
2001 至 2003
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671403/
关键词：
vital microscopy tumor microvessel vessel injury immune system anti-tumor lymphocyte 血管傷害

项目摘要

1), We established the method for making pulmonary metastasis of SAR) lung cancer in 2001. The process is as follows. SATO lung cancer was implanted to peritoneal cavity of Donryu rats for making cancerous ascites. Cancerous ascites was mixed with culture medium and was stored by -80℃ in a deep freezer. 0.2ml ascites containing 10^7 cancer cells was injected through the tail vein for making hematogenous pulmonary metastasis.2), We observed the formation process of tumor microcirculation in pulmonary metastasis of SARI) lung cancel, and studied anti-tumor lymphocyte action to tumor and tumor microvessels in 2002. Initial tumor of size 50 μ was found 3 days after cancer cells injection. The metastasis grew up to mature tumors of size 200-300 μ with tumor arterioles and tumor venules during 7 days. 5 days tumor had most numerous tumor microvessels. There were not any anti-tumor lymphocytes in the tumor.3), We treated mature pulmonary metastasis by following three methods in 2003 : single CDDP, single OK432, and OK432 with pretreatment of CDDP. OK432 with pretreatment of CDDP showed the best survival rate. In this group, many lymphocytes invading to tumor were observed.These experimental results indicate that tumor microvessel injury by some effective ways is necessary for activating immune system.

1) 2001年建立了SAR肺癌肺转移的制作方法。流程如下。将佐藤肺癌植入东柳大鼠腹腔制备癌变腹水。癌性腹水与培养基混合，-80℃低温冷冻保存。经尾静脉注入含有10^7个癌细胞的腹水0.2ml，使其形成血行性肺转移。2) 2002年，我们观察了SARI肺转移灶中肿瘤微循环的形成过程，并研究了抗肿瘤淋巴细胞对肿瘤及肿瘤微血管的作用。肿瘤细胞注射后3 d可见50 μ的初始肿瘤。7 d后，转移瘤发育成熟，大小为200 ~ 300 μ，肿瘤小动脉和肿瘤小静脉遍布。第5天肿瘤微血管最多。肿瘤中未见抗肿瘤淋巴细胞。3) 2003年，我们采用单药CDDP、单药OK432、OK432加CDDP预处理三种方法治疗成熟肺转移。经CDDP预处理的OK432存活率最高。本组观察到大量淋巴细胞侵袭肿瘤。这些实验结果表明，通过一些有效的方式损伤肿瘤微血管是激活免疫系统的必要条件。